Screener
Axsome Therapeutics AXSM Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Loan payable, long-term | 117,850 | 117,746 |
| Operating lease liability, long-term | 22,385 | 23,182 |
| Finance lease liability, long-term | 5,844 | 4,206 |
| Total liabilities | 659,020 | 601,510 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value per share (10,000,000 shares authorized, none issued and outstanding) | — | — |
| Common stock, $0.0001 par value per share (150,000,000 shares authorized, 51,420,445 and 50,882,766 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively) | 5 | 5 |
| Additional paid-in capital | 1,425,085 | 1,394,251 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's total liabilities?
- Axsome Therapeutics (AXSM) reported total liabilities of $659.02M in Q1 2026.
- How has Axsome Therapeutics's total liabilities changed year-over-year?
- Axsome Therapeutics's total liabilities increased by 21.3% year-over-year, from $543.47M to $659.02M.
- What is the long-term trend for Axsome Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Axsome Therapeutics's total liabilities has grown at a 52.7% compound annual growth rate (CAGR), from $72.34M to $601.51M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Axsome Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude